Literature DB >> 20128325

Metastatic cancer in solid tumors and clinical outcome: skeletal-related events.

Kyle O Rove1, E David Crawford.   

Abstract

Metastasis to the bone represents a frequent complication of visceral cancers, most commonly in patients with advanced breast, prostate, and lung cancer. More than 50% of patients with advanced breast or prostate cancer have identifiable bone metastasis, and 30% to 40% of patients with non-small-cell lung cancer ultimately develop metastases to bone. Most tumors preferentially metastasize to the axial skeleton, targeting the vertebrae, pelvis, proximal ends of long bones, and skull. Skeletal complications as a result of these metastases are widely recognized to increase mortality and decrease quality of life--specifically the loss of mobility, independence, and social functioning of a patient. Advances in understanding the mechanisms of metastasis to bone, the resulting physiologic disturbances that take place, screening, diagnosis, and availability of better treatment options are advancing clinicians' abilities to combat this devastating problem.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20128325

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

1.  CT-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures.

Authors:  Lorenzo Monfardini; Lorenzo Preda; Gaetano Aurilio; Stefania Rizzo; Vincenzo Bagnardi; Giuseppe Renne; Sara Maccagnoni; Paolo Della Vigna; Disalvatore Davide; Massimo Bellomi
Journal:  Radiol Med       Date:  2014-04-04       Impact factor: 3.469

2.  Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer.

Authors:  Wu-Gui Chen; Jing Sun; Wei-Wei Shen; Si-Zhen Yang; Ying Zhang; Xu Hu; Hao Qiu; Shang-Cheng Xu; Tong-Wei Chu
Journal:  Clin Exp Metastasis       Date:  2019-01-07       Impact factor: 5.150

3.  Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.

Authors:  Ying Jin; Xin An; Yu Chen Cai; Ye Cao; Xiu Yu Cai; Qing Xia; Yu Ting Tan; Wen Qi Jiang; Yan Xia Shi
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-13       Impact factor: 4.553

4.  A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model.

Authors:  Louis Doré-Savard; Nicolas Beaudet; Luc Tremblay; Yongjun Xiao; Martin Lepage; Philippe Sarret
Journal:  Clin Exp Metastasis       Date:  2012-09-06       Impact factor: 5.150

5.  Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis.

Authors:  Sabina Kaczanowska; Daniel W Beury; Vishaka Gopalan; Arielle K Tycko; Haiying Qin; Miranda E Clements; Justin Drake; Chiadika Nwanze; Meera Murgai; Zachary Rae; Wei Ju; Katherine A Alexander; Jessica Kline; Cristina F Contreras; Kristin M Wessel; Shil Patel; Sridhar Hannenhalli; Michael C Kelly; Rosandra N Kaplan
Journal:  Cell       Date:  2021-03-24       Impact factor: 66.850

Review 6.  The surgical treatment of pelvic bone metastases.

Authors:  Daniel A Müller; Rodolfo Capanna
Journal:  Adv Orthop       Date:  2015-02-24

7.  Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy.

Authors:  Zuozhang Yang; Zhenyi Su; Judy Park DeWitt; Lin Xie; Yongbin Chen; Xiaojuan Li; Lei Han; Dongqi Li; Junfeng Xia; Ya Zhang; Yihao Yang; Congguo Jin; Jing Zhang; Su Li; Kun Li; Zhiping Zhang; Xin Qu; Zewei He; Yanjin Chen; Yan Shen; Mingyan Ren; Zhongqin Yuan
Journal:  EBioMedicine       Date:  2017-04-11       Impact factor: 8.143

8.  Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events.

Authors:  Salvatore Grisanti; Susanna Bianchi; Laura D Locati; Luca Triggiani; Stefania Vecchio; Alberto Bonetta; Cristiana Bergamini; Pierfranco Conte; Mario Airoldi; Marco Merlano; Paolo Carlini; Toni Ibrahim; Ciro Rossetto; Salvatore Alfieri; Paolo Pronzato; Sandro Tonoli; Roberto Maroldi; Piero Nicolai; Carlo Resteghini; Stefano M Magrini; Alfredo Berruti
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

9.  Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

Authors:  Cheng Ai; Guangzhi Ma; Yunfu Deng; Qiangqiang Zheng; Yingcai Gen; Wen Li; Yang Li; Lingling Zu; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2020-02-05       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.